Soleil Would Be Aggressive Buyers of Akorn (AKRX) at Current Levels
More News related to AKRX
- Akorn, Inc. Signs Memorandum of Understanding with Bioluz S.A. for Five Premix Products
- Akorn Enters into a Five Year Contract Manufacturing Agreement to Supply an Ophthalmic Product
- Akorn, Inc. to Present at the Credit Suisse Healthcare Conference
- Morning Movers 11/04: Archer Daniels (ADM) Up on Results, Health Net (HNT) Sinks
- Akorn (AKRX) Tops Q3 EPS by 2c
More News related to Analyst Comments
- ENERTECH to Enter the Global Market with New EnerKeeper Power-Saving Device
- Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
- Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
- Silicon Motion Technology Corporation Announces Upcoming Schedule of Events With the Financial Community
- First Ever Collector Car Exchange in the United States with China
Soleil Securities Group is out with a research note this morning highlighting reasons why it would be "aggressive buyers" of Akorn (Nasdaq: AKRX) at current levels. The firm maintains its Buy rating and $8 price target on the stock.
The firm believes that Akorn will achieve several critical milestones by year-end:
- Approval for 8-10 additional branded/generic products
- Receipt of a potentially sizeable DTPA order from HHS, and
- Receipt of clarity from FDA on the clinical pathway for the longer-term vaccine opportunity
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in areas, such as ophthalmology, rheumatology, anesthesia, and antidotes primarily in the United States.
Related Categories
Analyst CommentsStocks Mentioned
-0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
